NurExone Biologic Inc.
PublicNurExone Biologic Inc. is now publicly traded
The data on this page reflects NurExone Biologic Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Early Funding
Aug 21, 2026
Total Funding Raised
$1.17M
Company Overview
NurExone Biologic Inc. is a pharmaceutical technology company developing a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries.
Sector
Healthcare
AI Layer
Non-AI
Keywords
NurExone Biologic Inc. Comparables
Compare NurExone Biologic Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aruna Bio, Inc. | 79% | |
| VivaZome Therapeutics | 78% | |
| ReNetX Bio | 76% |
NurExone Biologic Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 21, 2026 | ||||
| Private Placement | Jul 2, 2026 | ||||
| Private Placement | Mar 18, 2026 |
Key People
Founding team and executive leadership
Recent news
Latest coverage and updates
- partners_withSep 14, 2026
NurExone Biologic Inc. partnered with NanoPass Technologies Ltd. on Sep 14th '26.
NurExone Biologic Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access